References
Carr BR, Wilson JD. Disorders of the ovary and female reproductive tract. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison’s principles of internal medicine. 13th ed. v. 2. New York: McGraw-Hill, Inc., 1994: 2017–36
Jacobs S, Hillard TC. Hormone replacement therapy in the aged: a state of the art review. Drugs Aging 1996 Mar; 8: 193–213
Foster H, Balfour JA. Estradiol and dydrogesterone: a review of their combined use as hormone replacement therapy in postmenopausal women. Drugs & Aging 1997; 11(4): 309–32
Amy JJ. Femoston®: effects on bone and quality-of-life. Eur Menopause J 1995; 2 (4 Suppl): 16–22
Burch DJ, Spowart KJM, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β oestradiol. Br J Obstet Gynaecol 1995 Mar; 102: 243–8
Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997; 26: 219–26
van der Mooren MJ, Hanselaar AGJM, Borm GF, et al. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas 1994 Dec; 20: 175–80
Hänggi W, Lippuner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997 Jun; 104: 708–17
van der Mooren MJ. The influence of postmenopausal oestradioldydrogesterone therapy on blood pressure [abstract no. F179]. 8th International Congress on the Menopause; 1996 Nov 3–7; Sydney, Australia
Hänggi W, Lippuner K, Jaeger P, et al. The influence of postmenopausal replacement therapy on body composition [abstract]. Osteoporos Int 1996; 6 Suppl. 1: 230
Lees B, Pugh M, Siddle N, et al. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos Int 1995; 5(5): 344–8
Palacios S, Menéndez C. Changes in the BMD during micronized 17β-estradiol and dydrogesterone therapy in the postmenopausal women: a two-year prospective study [poster no. 127]. 11th Congress of European Association of Gynaecologists and Obstetricians; 1996 Jun 19–22; Budapest, Hungary
Lippuner K, Hänggi W, Birkhaeuser MH, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17-β estradiol and dydrogesterone. J Bone Miner Res 1997 May; 12(5): 806–12
ABPI data sheet compendium, 1996/97. London: Datapharma Publications Ltd, 1996: 1113–5
British National Formulary No. 34. London: The Pharmaceutical Press, 1997 Sep 316
Rights and permissions
About this article
Cite this article
Estradiol/dydrogesterone: HRT in a single tablet. Drugs Ther. Perspect 11, 1–5 (1998). https://doi.org/10.2165/00042310-199811080-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199811080-00001